NCT04576208View on ClinicalTrials.gov

A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2020

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
DRUG

TAK-788

TAK-788 capsules

DRUG

Antidiarrheal prophylaxis

Antidiarrheal prophylaxis includes loperamide tablet administered as per routine clinical practice.

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY